Plain-English translation of NCT06361888 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This trial is testing whether combining surufatinib with three other cancer medications works better than the standard two-drug treatment for pancreatic cancer that has spread to other parts of the body. Surufatinib is a new medication being added to help fight the cancer in a different way. The study will compare how well people do on the new four-drug combination versus the current standard treatment.
Pancreatic cancer that has spread is very difficult to treat, and current treatments don't work well enough for many patients. Researchers believe that adding this new medication to the standard treatment might help more patients live longer by attacking the cancer from multiple angles at once.
You likely qualify if…
You likely don't qualify if…
If you join this trial, you will be randomly assigned to receive either the new four-drug combination or the standard two-drug treatment. You will visit the clinic regularly to receive your medications (by injection or infusion), have blood tests to monitor your health and how the cancer responds, and have imaging scans to measure any changes in your tumors. The study involves about 500 patients across multiple hospitals, and your treatment will continue as long as the medication is helping and side effects are manageable.
AI-generated summary from trial data · Jun 18, 2026 · Not medical advice
China